Pharma Industry News

NICE backs Rozlytrek for subset of NSCLC patients

Rozlytrek is one of a new group of histology-independent cancer treatments designed to treat tumours regardless of where the primary tumour originatesOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]